Johnson & Johnson's New Study on Pasritamig Shows Promise Against Advanced Prostate Cancer Recent findings from Johnson & Johnson highlight pasritamig's effectiveness when used with docetaxel for advanced prostate cancer, paving the way for Phase 3 trials.

Johnson & Johnson's New Study on Pasritamig Shows Promise Against Advanced Prostate Cancer #United_States #Johnson_&_Johnson #Prostate_Cancer #Raritan,_NJ #pasritamig

Johnson & Johnson's Promising New Cancer Treatment Shows Early Success in Human Trials Johnson & Johnson has announced encouraging results for their new bispecific antibody, pasritamig, in prostate cancer treatment, demonstrating early anti-tumor activity.

Johnson & Johnson's Promising New Cancer Treatment Shows Early Success in Human Trials #United_States #Chicago #Johnson_&_Johnson #Prostate_Cancer #pasritamig